实用药物与临床
實用藥物與臨床
실용약물여림상
Practical Pharmacy and Clinical Remedies
2015年
10期
1181-1185
,共5页
卵巢癌%辅助化疗%血清肿瘤标志物
卵巢癌%輔助化療%血清腫瘤標誌物
란소암%보조화료%혈청종류표지물
Ovarian cancer%Neoadjuvant chemotherapy%Tumor markers
目的 探讨两种术后辅助化疗方案对卵巢癌患者的临床疗效及其对血清肿瘤标志物的影响.方法 以2010年10月至2013年2月我院妇产科收治的60例卵巢癌患者为研究对象,依据肿瘤细胞减灭术后辅助化疗方案的不同,随机将患者分为顺铂+紫杉醇方案组( TP组)和环磷酰胺+博来霉素+卡铂组( CBP组),每组各30例,比较两种辅助化疗方案的临床治疗效果及肿瘤标志物的变化. 结果 TP 组的治疗总体有效率为83. 33%,略高于CBP组的70. 00%,但差异无统计学意义(χ2 =1. 491,P=0. 222);两组患者的疾病控制率分别为96. 67%和80. 00%,TP组高于CBP组,差异有统计学意义(χ2 =4. 043,P=0. 044);随访结果显示,TP组患者中位生存时间为14. 0 个月,略高于CBP组的11. 9 个月,但两组间经Log-rank检验比较差异无统计学意义(χ2 =0. 585,P=0. 444);治疗后两组的血清肿瘤标志物均明显降低,其中CBP组患者的CYFRA21-1、CA125和CA19-9的降低幅度均明显高于TP组(P<0. 05). 结论 TP和CBP化疗辅助方案对卵巢癌均具有良好的临床疗效,TP组疾病控制率高于CBP方案,但CBP方案对血清肿瘤标志物水平的影响更为显著.
目的 探討兩種術後輔助化療方案對卵巢癌患者的臨床療效及其對血清腫瘤標誌物的影響.方法 以2010年10月至2013年2月我院婦產科收治的60例卵巢癌患者為研究對象,依據腫瘤細胞減滅術後輔助化療方案的不同,隨機將患者分為順鉑+紫杉醇方案組( TP組)和環燐酰胺+博來黴素+卡鉑組( CBP組),每組各30例,比較兩種輔助化療方案的臨床治療效果及腫瘤標誌物的變化. 結果 TP 組的治療總體有效率為83. 33%,略高于CBP組的70. 00%,但差異無統計學意義(χ2 =1. 491,P=0. 222);兩組患者的疾病控製率分彆為96. 67%和80. 00%,TP組高于CBP組,差異有統計學意義(χ2 =4. 043,P=0. 044);隨訪結果顯示,TP組患者中位生存時間為14. 0 箇月,略高于CBP組的11. 9 箇月,但兩組間經Log-rank檢驗比較差異無統計學意義(χ2 =0. 585,P=0. 444);治療後兩組的血清腫瘤標誌物均明顯降低,其中CBP組患者的CYFRA21-1、CA125和CA19-9的降低幅度均明顯高于TP組(P<0. 05). 結論 TP和CBP化療輔助方案對卵巢癌均具有良好的臨床療效,TP組疾病控製率高于CBP方案,但CBP方案對血清腫瘤標誌物水平的影響更為顯著.
목적 탐토량충술후보조화료방안대란소암환자적림상료효급기대혈청종류표지물적영향.방법 이2010년10월지2013년2월아원부산과수치적60례란소암환자위연구대상,의거종류세포감멸술후보조화료방안적불동,수궤장환자분위순박+자삼순방안조( TP조)화배린선알+박래매소+잡박조( CBP조),매조각30례,비교량충보조화료방안적림상치료효과급종류표지물적변화. 결과 TP 조적치료총체유효솔위83. 33%,략고우CBP조적70. 00%,단차이무통계학의의(χ2 =1. 491,P=0. 222);량조환자적질병공제솔분별위96. 67%화80. 00%,TP조고우CBP조,차이유통계학의의(χ2 =4. 043,P=0. 044);수방결과현시,TP조환자중위생존시간위14. 0 개월,략고우CBP조적11. 9 개월,단량조간경Log-rank검험비교차이무통계학의의(χ2 =0. 585,P=0. 444);치료후량조적혈청종류표지물균명현강저,기중CBP조환자적CYFRA21-1、CA125화CA19-9적강저폭도균명현고우TP조(P<0. 05). 결론 TP화CBP화료보조방안대란소암균구유량호적림상료효,TP조질병공제솔고우CBP방안,단CBP방안대혈청종류표지물수평적영향경위현저.
Objective To explore the clinical effect of two different postoperative neoadjuvant chemotherapy on patients with ovarian cancer and their influence on serum levels of tumor markers. Methods Sixty cases of ovarian cancer from October 2010 to February 2013 in our hospital were selected as research objects and randomly divided into cisplatin + paclitaxel group ( TP group) and cyclophosphamide + bleomycin + carboplatin group ( CBP group),30 cases in each group. The curative effects of the two adjuvant chemotherapy and theirs influence on tumor markers were compared. Results After treatment,the overall effective rate of TP group was 83. 33%,showing slightly higher than that of CBP group (70. 00%),but no significant difference was found between the two groups (χ2 =1. 491,P =0. 222);and the disease control rate of both two groups were 96. 67%and 80. 00%,TP group was significantly higher than CBP group ( P =0. 044 );The follow-up results showed that the median survival time of TP group was 14. 0 months,which was slightly higher than that of CBP group (11. 9 months),but the Log-rank test demonstrated that there was no significant difference between the two groups in survival time (χ2 =0. 585,P=0. 444). After treatment,the ser-um tumor markers significantly decreased in two groups,and the decrease levels of CYFRA21-1,CA125 and CA19-9 of CBP group were significantly higher than those of TP group ( P<0. 05 ) . Conclusion TP and CBP adjuvant chemo-therapy scheme have good clinical effect on cervical squamous cell carcinoma,the disease control rate of TP group is higher than CBP group,but the CBP scheme is more effective to improve the level of serum tumor markers.
